Janssen’s Stelara overtakes Takeda’s Entyvio as the leading alternative MOA in Crohn’s Disease, but pressure is on to maximize IBD value in advance of pipeline drugs from Celgene (mongersen, ozanimod), Roche/Genentech (etrolizumab) and Pfizer (Xeljanz)

According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use in IBD is becoming increasingly dynamic, with switching rates up significantly in both Ulcerative Colitis (UC) and Crohn’s Disease (CD)…

Continue Reading

Keryx’s Auryxia and Vifor-FMC’s Velphoro Slowly Gaining Share in the Phosphate Binder Market While Big Shifts in CKD-MBD Loom With the Pending Introduction of Amgen’s Parsabiv

Over 300 US nephrologists and renal dietitians (RD) describe future practice pattern changes in most recent quarterly update by Spherix Global Insights. Download Report Overview EXTON, Pa., May 10, 2017 /PRNewswire/ — In a market long dominated by Sanofi-Genzyme’s Renvela,…

Continue Reading

EU Rheumatoid Arthritis Landscape Poised for Big Changes as Rheumatologists Plan for the Adoption of Eli Lilly/Incyte’s Olumiant, Pfizer’s Xeljanz, and Regeneron/Sanofi’s Kevzara

With the recent approval of two new JAK inhibitors and the imminent introduction of additional IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management. Download Report Overview EXTON, Pa., May 4, 2017 /PRNewswire/ — Spherix Global Insights recently…

Continue Reading
← Newer Posts
Older Posts →